Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer
Clinical trial NCT06748508 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06748508
- Sponsor
- Fudan University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-25
- Primary completion
- 2027-07-25
- Enrollment
- 141
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.